Novogen has an ovarian cancer drug (developed by Novogen) that completes Phase 1 in 2018.
A proposed name change to Kazia Therapeutics reflects the new lead compound and the arrival of a highly-experienced management team, led by Dr James Garner.
We value Novogen at 8 cents per share base case and 26 cents per share optimistic case. Our target price of 17 cents per share sits at the midpoint of our valuation range. We see Novogen being re-rated by the progress into the clinic of GDC-0084.
Heres the thing
JG took Kazia from 8c to $1.90c
Well Sam
Im really happy with that
: He obviously has contacts here and the US.
- Forums
- ASX - By Stock
- PER
- Ann: Chief Executive Officer and Managing Director Appointment
Ann: Chief Executive Officer and Managing Director Appointment, page-48
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38503 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 194063 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.099 |
2 | 108491 | 0.098 |
1 | 30927 | 0.097 |
1 | 10004 | 0.096 |
3 | 162157 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 194063 | 5 |
0.110 | 254663 | 3 |
0.115 | 1334300 | 6 |
0.120 | 381142 | 9 |
0.125 | 110429 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |